Cover Image
市場調查報告書

膽管癌:開發平台分析

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 237881
出版日期 內容資訊 英文 492 Pages
訂單完成後即時交付
價格
Back to Top
膽管癌:開發平台分析 Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2016
出版日期: 2016年12月14日 內容資訊: 英文 492 Pages
簡介

膽管癌的症狀有腹部的不適感、食欲不振、發燒、體重減輕。這個疾病的代表性治療法有化療及放射線治療等。

本報告提供全球膽管癌治療藥的開發中產品概要,提供您目前開發平台狀況和最新趨勢,後期階段及中止的計劃等資訊,還有主要企業及他們開發中的產品評估等。

簡介

  • 調查範圍

膽管癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

膽管癌:企業開發中的治療藥

膽管癌:大學/機關研究中的治療藥

膽管癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

膽管癌:企業開發中的產品

膽管癌:大學/機關研究中的產品

膽管癌的治療藥的開發企業

  • 4SC AG
  • Adgero Biopharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.
  • Ariad Pharmaceuticals, Inc.
  • ArQule, Inc.
  • Array BioPharma Inc.
  • Arrien Pharmaceuticals, LLC
  • Aslan Pharmaceuticals Pte. Ltd.
  • Bavarian Nordic A/S
  • Bayer AG
  • Blueprint Medicines Corporation
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • CellAct Pharma GmbH
  • Cellceutix Corporation
  • Cellular Biomedicine Group, Inc.
  • Concordia Healthcare Corp.
  • Cornerstone Pharmaceuticals, Inc.
  • Delcath Systems, Inc.
  • Eisai
  • Eli Lilly and Company
  • Exelixis, Inc. 其他

膽管癌:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • vandetanib
  • AP-5346
  • cabozantinib s-malate
  • elpamotide
  • exatecan mesylate
  • LY-2801653
  • NUC-1031
  • AG-120
  • Im-01
  • PAN-622
  • ARN-5032
  • JP-1584

膽管癌:最近的開發平台趨勢

膽管癌:暫停中的計劃

膽管癌:開發中止的產品

膽管癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8808IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2016, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline landscape.

Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers) and weight loss. Treatment includes chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 49, 18, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 4 molecules, respectively.Bile Duct Cancer (Cholangiocarcinoma).

Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Bile Duct Cancer (Cholangiocarcinoma) Overview
  • Therapeutics Development
  • Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies
  • Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance
  • Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies
  • Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes
  • Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development
  • Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment
  • Drug Profiles
  • Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects
  • Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products
  • Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2016
  • Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by 4SC AG, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ariad Pharmaceuticals Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ArQule Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Array BioPharma Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Arrien Pharmaceuticals LLC, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bavarian Nordic A/S, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by BeiGene Ltd, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Blueprint Medicines Corp, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celgene Corp, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by CellAct Pharma GmbH, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellceutix Corp, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellular Biomedicine Group Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Concordia International Corp, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Delcath Systems Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eisai Co Ltd, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eli Lilly and Company, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Exelixis Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by H3 Biomedicine Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Halozyme Therapeutics Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Hutchison MediPharma Ltd, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Incyte Corp, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Innopharmax Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by INSYS Therapeutics Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Johnson & Johnson, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Komipharm International Co Ltd, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Loxo Oncology, Inc., H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Mebiopharm Co Ltd, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by MedImmune LLC, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merck & Co Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NanoCarrier Co Ltd, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NormOxys Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Novartis AG, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NuCana BioMed Ltd, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Oasmia Pharmaceutical AB, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by OncoTherapy Science Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Panacea Pharmaceuticals Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by PCI Biotech Holding ASA, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pfizer Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pharma Mar SA, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Provecs Medical GmbH, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Puma Biotechnology Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by RedHill Biopharma Ltd, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sanofi, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Senhwa Biosciences Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by SynCore Biotechnology Co Ltd, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by SyntheX Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Taiwan Liposome Company Ltd, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by tella Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Threshold Pharmaceuticals Inc, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by VasGene Therapeutics Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects (Contd..1), H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects (Contd..2), H2 2016
  • Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2016
  • Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top